- Home
- ONCT
as 07-26-2024 4:00pm EST
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 22.9M | IPO Year: | N/A |
| Target Price: | $28.33 | AVG Volume (30 days): | 6.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.57 - $13.20 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,151,000 | Revenue Growth: | 21.54% |
| Revenue Growth (this year): | 55.67% | Revenue Growth (next year): | -33.22% |
Stock Insider Trading Activity of Oncternal Therapeutics Inc. (ONCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wills Robert James | ONCT | Director | Apr 8 '24 | Buy | $8.96 | 3,086 | $27,654.57 | 10,000 | SEC Form 4 |
| Wills Robert James | ONCT | Director | Mar 28 '24 | Buy | $8.48 | 6,914 | $58,602.37 | 6,914 | SEC Form 4 |
| HALE DAVID F | ONCT | Director | Feb 23 '24 | Buy | $9.04 | 714 | $6,454.56 | 714 | SEC Form 4 |
| HALE DAVID F | ONCT | Director | Feb 23 '24 | Buy | $9.04 | 266 | $2,404.64 | 29,673 | SEC Form 4 |
| Wills Robert James | ONCT | Director | Feb 23 '24 | Sell | $9.04 | 980 | $8,859.20 | 0 | SEC Form 4 |
Latest Oncternal Therapeutics Inc. News
ONCT Breaking Stock News: Dive into ONCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
GlobeNewswire
15 days ago
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
Compare ONCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONCT Oncternal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.